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Idiopathic pulmonary fibrosis (IPF) is a degenerative
disease of the lungs with an average survival post-
diagnosis of 2–3 years. New therapeutic targets
and treatments are necessary. Mutations in compo-
nents of the telomere-maintenance enzyme telome-
rase or in proteins important for telomere protection
are found in both familial and sporadic IPF cases.
However, the lack of mouse models that faithfully
recapitulate the human disease has hampered new
advances. Here, we generate two independent
mouse models that develop IPF owing to either crit-
ically short telomeres (telomerase-deficient mice) or
severe telomere dysfunction in the absence of telo-
mere shortening (mice with Trf1 deletion in type II
alveolar cells). We show that both mouse models
develop pulmonary fibrosis through induction of
telomere damage, thus providing proof of principle
of the causal role of DNA damage stemming from
dysfunctional telomeres in IPF development and
identifying telomeres as promising targets for new
treatments.
INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is a life-threatening lung
degenerative disease that lacks current effective treatments
(King et al., 2011). The mean survival time upon diagnosis is
only 2 to 3 years (King et al., 2011). The clinical course of the
disease is characterized by a progressive decline in exercise
capacity, difficulty breathing, recurrent infections, and severe
impairment in lung function, which makes the patients depen-
dent on long-term oxygen treatment. IPF is characterized by
the presence of lung scarring, immune infiltrates, and inflamma-
tion, which in the past two decades has led to the exploration of
inflammation as a therapeutic target for treatment of the disease
(Selman et al., 2001). Unfortunately, recent clinical trials for IPF
patients based on immune suppression had to be interrupted
owing to the toxicity of the treatment (Martinez et al., 2014).
More recently, IPF has been proposed to be the result of repet-286 Cell Reports 12, 286–299, July 14, 2015 ª2015 The Authorsitive epithelial cell injury and defective regeneration, but the pre-
cise molecular cause of damage or defective regeneration
remains unclear (Hinz et al., 2007; Ryu et al., 2014). To date,
lung transplantation is the only therapeutic option for less than
5% of IPF patients with very severe disease (Lama, 2009).
IPF is an age-associated disease, with a mean age at onset
between 50 and 70 years (Armanios, 2013; King et al., 2011),
and affects men more frequently than women (2:1 ratio) (King
et al., 2011). Environmental factors known to inflict damage to
lung epithelial cells, such as smoking, are known to increase
the risk of developing IPF (Armanios, 2013; King et al., 2011).
One of the hallmarks of aging in mice and humans is the pro-
gressive shortening of telomeres with increasing age (Lo´pez-
Otı´n et al., 2013). Mammalian telomeres are protective structures
at the ends of chromosomes (Blackburn, 2001; de Lange, 2005)
that consist of TTAGGG repeats bound by a six-protein complex
known as shelterin (de Lange, 2005). A minimum length of telo-
meric repeats is necessary for shelterin binding and telomere
protection (Blackburn, 2001; de Lange, 2005). Telomerase
(Tert, telomerase reverse transcriptase) is an enzyme capable
of compensating the telomere attrition produced by telomere
degradation and/or by the incomplete replication of telomeric re-
peats associated with each DNA replication cycle through de
novo addition of TTAGGG repeats to the chromosome ends.
To this end, telomerase uses an associated RNA component
as replication template (Terc, telomerase RNA component)
(Greider and Blackburn, 1985). In mice and humans, telomerase
is silenced after birth, leading to progressive telomere shortening
associated with cell division throughout the lifespan (Canela
et al., 2007; Flores et al., 2008; Harley et al., 1990; Vera et al.,
2012). When telomeres reach a critically short length, this trig-
gers activation of a persistent DNA damage response at telo-
meres and the subsequent induction of cellular senescence or
apoptosis. In the case of adult stem cells, critical telomere short-
ening impairs their ability to regenerate tissues both in mice and
humans, leading to many different age-related pathologies
(Flores et al., 2005). Interestingly, telomere shortening has
been shown to be influenced both by genetic factors (ie., muta-
tions in genes necessary for telomere maintenance) and
environmental factors (ie., cigarette smoke has a negative effect)
(Armanios, 2013; King et al., 2011).
Compelling evidence that telomere shortening contributes to
aging and age-related disease comes from the study of humans
and mice with defective telomerase activity (Armanios and
Blackburn, 2012; Blasco, 2005, 2007). In particular, the first
demonstration that short telomeres were sufficient to cause
age-related pathologies and decreased longevity came from a
study of telomerase-deficient mice, which show premature
aging phenotypes both in low-proliferating (heart and brain)
and high-proliferating compartments (bone marrow, gut, skin,
and testis) (Blasco et al., 1997; Ferro´n et al., 2004; Herrera
et al., 1999; Lee et al., 1998; Leri et al., 2003). Importantly, telo-
merase-deficient mice show worsening of phenotypes with
increasing mouse generations owing to inherited progressively
shorter telomeres, with the later generations showing severe
phenotypes and premature death at pre-reproductive ages (Gar-
cı´a-Cao et al., 2002; Herrera et al., 1999; Lee et al., 1998). This
phenomenon first indicated genetic anticipation associated
with telomerase deficiency. In humans, a number of conditions
have been also associated with mutations in telomerase and
other telomere-related genes, with the most frequent condition
being IPF (Armanios, 2013; Armanios and Blackburn, 2012). In
particular, mutations in Tert and Terc account for 8%–15% of
familial and 1%–3% of sporadic cases (Alder et al., 2008; Arma-
nios, 2013; Armanios et al., 2007). More recently, telomerase
mutations leading to abnormally short telomeres have also
been found in up to 1% of smokers with chronic obstructive pul-
monary disease (COPD) (Stanley et al., 2015). In addition to lung
disease, humans with mutations in telomere maintenance genes
show a variety of pathologies and disease states that have been
collectively named ‘‘telomere syndromes’’ (Armanios and Black-
burn, 2012) and that affect both highly proliferative (bone
marrow, gut, and skin) and slow-proliferative (liver, lung, and
pancreas) tissues. As in mice, disease anticipation is also found
in human families with telomere syndromes, with the mutation
generally first manifesting in adults with pulmonary fibrosis and
the more severe phenotypes appearing in pediatric populations
(immunodeficiency) and young adults (aplastic anemia) from the
next generations (Armanios, 2013).
Although pulmonary fibrosis and emphysema are the most
frequent manifestations of telomere defects in humans,
telomerase-deficient mice with critically short telomeres do
not spontaneously develop pulmonary disease. Exposure
to cigarette smoke, which is known to accelerate disease
onset in humans, induces emphysema in telomerase-deficient
mice (Alder et al., 2011). It has recently been shown that
alveolar progenitor senescence induced by telomere dysfunc-
tion is sufficient to recapitulate the regenerative defects,
inflammatory responses, and susceptibility to injury that are
characteristic of human telomere-mediated lung disease,
although no IPF was reported in these mouse models (Alder
et al., 2015). These findings suggest that additional damage,
or telomere damage of higher severity, may be required for
IPF onset in mice.
Thus, mousemodels that more closely recapitulate themolec-
ular features of human disease, including telomere defects, are
necessary. These models will aid in our understanding of the
pathobiology of IPF and will allow more efficient preclinical
testing of novel therapeutic strategies. To this end, we first tested
whether a source of telomere damage of a higher intensity than
that achieved by telomere shortening with increasing mousegenerations in the absence of telomerase was sufficient to
induce IPF in mice.
In this regard, proper telomere capping requires not only a
minimum length of telomere repeats but also the integrity of a
six-protein complex known as shelterin, which is bound to
telomeric repeats (de Lange, 2005). Out of the six shelterin
components, TRF1 was the first to be identified (Chong et al.,
1995). Extensive work using genetically modified mouse
models has shown that Trf1 deletion leads to an immediate
and persistent DNA damage response at chromosome ends,
leading to severe proliferative defects in all the tissues studied,
including stem cell compartments, thus recapitulating some of
the pathologies associated with telomere syndromes (Beier
et al., 2012; Martı´nez et al., 2009; Schneider et al., 2013). Inter-
estingly, the TRF1-interacting shelterin protein TIN2 has also
been found to be mutated in telomere syndromes, indicating
that severe telomere uncapping, even in the absence of telo-
mere shortening, also leads to disease. However, the role of
shelterin dysfunction in pulmonary fibrosis has not been
formally addressed.
RESULTS
Trf1 Deletion in the Lung Induces Pulmonary Fibrosis
and Decreases Mouse Survival
We induced severe telomere dysfunction specifically in the lungs
by genetically deleting the shelterin component Trf1 from
epithelial type II alveolar cells, which have been proposed to
contribute to lung progenitor cells (Desai et al., 2014; Rawlins,
2015) (Experimental Procedures). In particular, to specifically
delete Trf1 in the lungs, we generated the Trf1lox/lox SFTPC-
CreERT2KFPlox-STOP-loxmousemodel. In thismodel, Cre recombi-
nase expression is controlled by the surfactant proteinC (SFTPC)
promoter, which is specific for type II alveolar cells, andCreERT2 is
conditionally activated by tamoxifen (TMX) administration (Rock
et al., 2011). In addition, a transgene encoding for the fluorescent
katushka (KFP) protein that contains a stop cassette flanked by
lox sequenceswas introduced as a reporter tomonitor Cre activ-
ity (Figure 1A). TMXwas administered intraperitoneally (i.p.) every
second day for 6 weeks to induce both Trf1 deletion and KFP
expression (Figure 1B). After 2weeksof TMX treatment,wequan-
tified the amount of KFP-positive cells in the lungs of Trf1lox/lox
SFTPC-CreERT2 KFPlox-STOP-lox mice and Trf1+/+ SFTPC-CreERT2
KFPlox-STOP-lox control mice by immunohistochemistry. In both
genotypes, we found that 1 week after TMX treatment, 14%
of the total lung cells were KFP positive (Figure 1C; see also
Figure 3F), which is in agreement with the previously reported
abundance of alveolar type II cells (12%–15%) in whole lung
cell populations (Dobbs, 1990; Van der Velden et al., 2013).
We next confirmed Trf1 deletion in the lungs of Trf1lox/lox
SFTPC-CreERT2 KFPlox-STOP-lox mice by PCR amplification of
the Trf1D allele (Figure 1D). Triple immunofluorescence staining
with SFTPC, KFP, and TRF1 antibodies clearly demonstrated
that all of the SFTPC-positive cells were also KFP positive and
that these cells stained negative for TRF1 in the lungs of Trf1lox/
lox mice (Figures 1E and 1F). These results indicate efficient Cre
expression in alveolar type II cells and Trf1 deletion in the lungs
of Trf1lox/lox SPC-CreERT2 KFPlox-STOP-lox mice.Cell Reports 12, 286–299, July 14, 2015 ª2015 The Authors 287
Figure 1. Efficient Trf1 Deletion in Alveolar Type II Cells upon Tamoxifen Administration
(A) Genetic model. Trf1lox, KFP Lox-STOP-Lox, and SFTPC-CreERT2 alleles are depicted before and after Cre-mediated excision.
(B) Tamoxifen (TMX) intraperitoneal treatment and in vivo imaging schedule. 8- to 10-week-old mice were i.p. injected with TMX three times a week for 6
consecutive weeks. At weeks 5 and 9 from the beginning of the TMX treatment, micewere analyzed by computed tomography (CT), and at week 16, the remaining
alive mice were sacrificed for histological analysis.
(C) Representative images of KFP staining of Trf1+/+ SFTPC-Cre-ERT2 KFPCAG-lox-STOP-lox and Trf1flox/flox SFTPC-CreERT2 KFPCAG-lox-STOP-lox lung sections after
1 week of TMX treatment. The percentage of KFP-positive cells with regard to the total lung cell population is indicated.
(D) Analysis of Trf1 excision by PCR in lung samples. Note that lung cell populations that are not alveolar type II give rise to TRF1lox allele amplification.
(legend continued on next page)
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Interestingly, 4–8 weeks after TMX treatment, we observed
that 42% of the TRF1-deficient mice of both genders and 65%
of male mice in which we specifically deleted Trf1 in lung epithe-
lial alveolar type II cells showed an abnormal computed tomog-
raphy (CT) pattern compatible with fibrosis, while none of the
wild-type animals showed this abnormal CT pattern (Figures 2A
and 2B). This abnormal radiological pattern is characterized by
presence of reticular opacities with honeycombing, also typically
found in humanpulmonary fibrosis patients (Figure 2A) (Ryu et al.,
2014). Notably, the radiologic lesions detected by CT occupied
the large majority of the lungs (up to 100% of the lung volume),
indicative of very severe lesions (Figure 2C). In agreement with
this severity, 42% of TRF1-deficient mice had to be sacrificed
during the first 8 weeks of TMX treatment owing to severe respi-
ratory defects, characterized by the presence of labored and
heavy breathing, leading to a significantly decreased survival
compared to the wild-type treated controls (Figure 2D).
For definite diagnosis of pulmonary fibrosis as the cause of the
abnormal radiological pattern observed in TRF1-depleted lungs,
we performed full histopathology of the lungs following mouse
sacrifice. As pulmonary fibrosis is characterized by formation
of fibrotic scars, we determined the presence of collagen fiber
deposits by using Masson trichrome staining (Experimental Pro-
cedures). We observed that more than 40% of the TRF1-
deficient mice of both genders and 65% of male mice showed
pathological findings characteristic of pulmonary fibrosis (Fig-
ures 2E and 2F). In particular, these mice showed extensive
pneumonia (between 40% and 50% of the lung parenchyma
affected), inflammatory infiltrates consisting mainly of macro-
phages with hemosiderin content indicative of traumatic hemor-
rhage, and intense inflammation that were absent in wild-type
lungs (Figure 2E). Also in agreement with human findings, we de-
tected an increased presence of macrophage infiltrates and the
activation of an inflammatory response as indicated by specific
staining for F4/80 and interleukin-6, respectively (Figure 2E).
Deposition of collagen fibers was also visualized by sirius red
staining using polarized light for detection (Experimental Proce-
dures) (Broytman et al., 2015). We detected a 6-fold higher
amount of collagen fibers in the Trf1-deleted fibrotic lungs
compared to the wild-type controls (Figures 2G and 2H). This
was also confirmed by higher collagen expression levels in
TRF1-depleted lungs (Figure 2I). In addition, we also observed
increased numbers of a-smooth muscle actin (a-SMA)-positive
myofibroblasts, which have been associated with fibrotic lungs
(Zhang et al., 1996) (Figures 2J and 2K). Together, these findings
confirm extensive fibrosis as a consequence of TRF1 depletion
in alveolar type II cells.
Trf1 Deletion in Alveolar Type II Cells Leads to Cell
Death without Inducing Telomere-Length Changes in
Lung Cells
Next, we investigated the underlying molecular consequences
of Trf1 deletion in the lung that trigger disease. First, we consid-(E) Representative images of triple-immunofluorescence staining of KFP (purple),
Trf1flox/flox SFTPC-CreERT2 KFPCAG-lox-STOP-lox lung sections after 2 weeks of TMX
(F) Quantification of the percentage of KFP- and TRF1-positive cells with regard
represent SE. The number of mice analyzed per genotype is indicated. ***p < 0.0ered the hypothesis that TRF1 deficiency may lead to
decreased telomere length by forcing extra proliferation of the
remaining, non-Trf1-deleted lung epithelial cells. In particular,
we recently described that Trf1 deletion in the bone marrow
led to depletion of the stem cell compartment and to extra pro-
liferation of the remaining non-Trf1-deleted progenitor cells,
leading to very rapid telomere shortening in the bone marrow
(Beier et al., 2012). To this end, we performed telomere quan-
titative fluorescence in situ hybridization (qFISH) directly on
lung sections (Experimental Procedures). However, we did
not detect decreased telomere fluorescence in the TRF1-
depleted lungs at the time of onset of pulmonary fibrosis
(5–8 weeks after induction of deletion) compared to the wild-
type controls. In particular, we did not observe differences
either in the mean telomere spot fluorescence intensity or in
the mean total nuclear telomere fluorescence between TMX-
treated Trf1lox/lox SPC-CreERT2 KFPlox-STOP-lox mice and wild-
type controls (Figures 3A, 3B, and 3E). Similarly, we did not
observe an increased frequency of telomere spots with low
fluorescence (<50 and <60 arbitrary units of fluorescence) cor-
responding to the 10th and 20th percentile of the wild-type telo-
mere fluorescence distribution in the TRF1-deleted lungs,
which is indicative of the presence of very short telomeres (Fig-
ures 3C–3E). These results are in agreement with the fact that
the lung is a low-proliferative compartment with a cell turnover
estimated to be less than 2% per week in alveolar epithelial
cells (Alder et al., 2011).
Interestingly, we observed that the initial amount of KFP-pos-
itive cells (15% for both genotypes) dramatically decreased in
Trf1-deleted lungs compared to wild-type lungs 6–8 weeks after
TMX treatment (Figures 3F and 3I), which strongly suggests elim-
ination of alveolar type II cells as a consequence of Trf1 deletion.
Indeed, at the death point, while 12% of alveolar type II cells in
Trf1 wild-type lungs were KFP positive (Dobbs, 1990; Van der
Velden et al., 2013), less than 5% of alveolar type II cells in
Trf1-deleted fibrotic lungs were KFP positive, indicating that
two-thirds of these cells were eliminated during the course of
the experiment (Figures 3F and 3I). Abrogation of TRF1 in
proliferative tissues such as the stratified epithelia induces telo-
meric DNA damage and a rapid DNA damage response charac-
terized by the activation of p53/p21 pathways (Martı´nez et al.,
2009). Immunohistochemistry analysis of lung sections readily
revealed that the number of p53- and p21-positive cells signifi-
cantly increased in TRF1-depleted alveolar type II cells, indica-
tive of cellular senescence (Figures 3G–3I). The number of
p21-positive cells relative to KFP-positive cells progressively
increased throughout the course of the experiment. Further sup-
porting induction of cellular senescence, we also detected
increased numbers of the p19 protein in TRF1-depleted lungs
(Figures 3H and 3I) (Collado et al., 2007). In addition, we also de-
tected increased numbers of active caspase 3 (C3a)-positive
cells in TRF1-depleted lungs, indicative of apoptosis (Figures
3H and 3I). Thus, both senescence markers and apoptosisSFTPC (green), and TRF1 (red) Trf1+/+ SFTPC-Cre-ERT2 KFPCAG-lox-STOP-lox and
treatment.
to SFTPC-positive cells. A t test was used for statistical analysis. Error bars
01.
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Figure 2. Trf1 Deletion in the Lung Induces Pulmonary Fibrosis and Decreases Mouse Survival
(A) Representative CT images of Trf1+/+ and affected Trf1D/D lungs.
(B) Percentage of mice of both genders or only males with an abnormal CT pattern at week 9 after the beginning of TMX treatment. An c2 test was used for
statistical analysis.
(C) Quantification of the affected lung volume. A t test was used for statistical analysis.
(legend continued on next page)
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are induced as a consequence of TRF1 ablation in alveolar type II
cells.
Double-immunofluorescence staining with gH2AX and TRF1
antibodies showed a significant progressive increase in the
number of gH2AX-positive damaged cells (reaching 10% of
the total lung cell population 6–8 weeks after the beginning
of TMX treatment) that were negative for TRF1 staining,
demonstrating that TRF1 abrogation results in telomeric DNA
damage (Figures 3J and 3K). Given that wild-type lungs did
not appear to have damaged cells (<1% of total lung cells)
and the percentage of damaged cells in Trf1-deleted lungs
(10%) was similar to the total number of alveolar type II cells
(10%–15%) (Dobbs, 1990; Van der Velden et al., 2013), our
observations suggest that at least 90% of the total alveolar
type II cells lacking TRF1 show DNA damage. This increase
in gH2AX-positive cells could also be a consequence of the
anticipated inflammatory response observed in TRF1-deficient
lungs (Figure 2E).
In summary, these findings demonstrate that acute telomere
dysfunction in lung epithelial cells, such as that triggered by
abrogation of the TRF1 shelterin component in alveolar type II
cells, is sufficient to rapidly induce massive pulmonary fibrosis
in mice through induction of DNA damage, p21/p53 cell-cycle in-
hibitors, and elimination of alveolar type II cells. Thus, we have
generated a mouse model that develops IPF induced by telo-
mere defects in the absence of additional damaging agents.
These findings also highlight the involvement of alveolar type II
cells in the development of pulmonary fibrosis.
ALowBleomycin Dose Synergizeswith Short Telomeres
to Trigger Pulmonary Fibrosis
As pulmonary fibrosis induced by TRF1 deletion, although a
consequence of severe telomere dysfunction, did not present
with one of the features of human IPF associated with telomere
syndromes (namely, the presence of short telomeres), we next
sought to develop a mouse model for IPF based on telomerase
deficiency that recapitulates the short telomere phenotype. As
mentioned above, previous reports have shown that mice defi-
cient for the telomerase RNA essential component Terc (Terc/)
do not spontaneously develop IPF and that emphysema is the
only pulmonary pathology that develops, even when they are
subjected to additional cellular damaging agents, such as ciga-
rette smoke (Alder et al., 2011).
Based on the results obtained with the TRF1-deficient model,
which suggested that a high burden of telomeric DNA damage in
alveolar type II cells (>90% of these cells with damage) was suf-
ficient to trigger full-blown pulmonary fibrosis, we reasoned that(D) Survival curve of Trf1+/+ (n = 15) and Trf1D/D (n = 12) mice. A log-rank test wa
(E) Representative H&E, Masson’s trichrome, F4/80, and interleukin-6 staining im
macrophages and hemosiderophages (red arrowheads), polymorphonuclear leu
deposits (black arrowheads) are indicated. Amplified Masson trichrome images
(F) Percent of mice of both genders or only males diagnosed with pulmonary fib
(G) Representative images of Trf1+/+ and affected Trf1D/D lung sections stained w
fibers are bright orange.
(H) Percentage of lung area filled with collagen fibers.
(I and J) Representative image and quantification of a-SMA-positive myocyte sta
(K) Transcriptional levels of collagen expression of collagen in Trf1+/+ and affecte
Error bars represent SE. The number of mice analyzed per genotype is indicatedapplication of DNA-damaging agents to telomerase-deficient
mice with short telomeres may be sufficient to increase the
burden of DNA damage in the lungs of these mice and to trigger
pulmonary fibrosis.
In this regard, bleomycin is widely used to induce acute pul-
monary fibrosis in mice (Mouratis and Aidinis, 2011). In partic-
ular, treatment of wild-type mice with a single dose of 2.5 g/kg
body weight (BW) bleomycin leads to development of severe
fibrotic lesions in the lung as early as 2 weeks post-treatment.
However, upon removal of the treatment, these lesions do not
progress in time, and many of them eventually regress, most
likely owing to lung regeneration by the non-affected cells (Mour-
atis and Aidinis, 2011). This fact has been an important short-
coming for the use of bleomycin-induced pulmonary fibrosis
mouse models for the development of new treatments.
Here, we subjected Tert/ mice from the second and fourth
generations (G2 and G4, respectively) with progressively shorter
telomeres, as well as wild-type controls, to a small dose of bleo-
mycin that is not sufficient to induce pulmonary fibrosis in wild-
type mice but could perhaps synergize with short telomeres in
the context of the telomerase-deficient background (Blasco
et al., 1997) (Figures 4A–4C). To determine the maximum bleo-
mycin dose that does not induce pulmonary fibrosis in wild-
type mice, we subjected wild-type mice to 2.5 mg/kg BW,
1 mg/kg weight, 0.5 mg/kg BW, and 0.1 mg/kg BW bleomycin
and found that themaximum dose that did not induce pulmonary
fibrosis was 0.5 mg/kg BW (Figure 4C). Thus, we selected this
low dose of bleomycin for further experiments. We first sub-
jected second-generation (G2) and G4 Tert/ mice, as well as
wild-type controls, to 0.5 mg/kg BW bleomycin and radiologi-
cally followed their lungs by CT (Figure 4B). Two to four weeks
after treatment with low doses of bleomycin, we observed that
30% and 25% of G2 and G4 Tert/ mice, respectively,
compared to 10% of wild-type control mice, presented
abnormal radiological images of the lung (Figures S1A and
S1B). When only males were taken into account, we observed
that 50% and 45% of G2 and G4 Tert/ mice, respectively,
compared to 20% of wild-type control mice, presented
abnormal radiological images of the lung, indicating a tendency
toward more Tert/ males than females presenting abnormal
CT patterns (Figures S1A and S1B). Interestingly, we noted
that these abnormal CT pattern disappeared with time in the
case of wild-type mice, indicating that they could correspond
to an inflammatory reaction to bleomycin treatment. In contrast,
after 10 weeks, both G2 and G4 Tert/ mice showed an
abnormal CT pattern in 50% of the affected initial lung volume
suggestive of pulmonary fibrosis (Figure S1C).s used for statistical analysis of the survival curve.
ages of Trf1+/+ and affected Trf1D/D lungs. Different types of infiltrates including
kocytes (orange arrowheads), lymphocytes (blue arrowheads), and collagen
are shown.
rosis by histopathological analysis. A t test was used for statistical analysis.
ith sirius red and visualized by bright-field and polarized light, where collagen
ining.
d Trf1D/D lungs. A t test was used for statistical analysis.
. *p = 0.05; **p < 0.01; ***p < 0.001.
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Figure 3. Trf1 Deletion in Alveolar Type II Cells Leads to Cell Death without Inducing Telomere-Length Changes in Lung Cells
(A–D) Individual mean telomere length (A), total mean nuclear telomere length (B), percentage of short telomeres <50 arbitrary units of fluorescence (a.u.f.)
corresponding to the 10th percentile of wild-type telomere distribution (C), and percentage of short telomeres <60 a.u.f. corresponding to the 20th percentile of
wild-type telomere distribution (D) in Trf1+/+ and Trf1D/D lungs.
(E) Representative images of telomere qFISH analysis.
(legend continued on next page)
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To confirm presence of lung disease, we performed full histo-
pathological analysis of the lungs from fourth to tenth week post
treatment and used Masson trichrome staining to highlight
fibrotic areas. Strikingly, 50%–25% of G2 and G4 Tert/ mice
subjected to low-dose bleomycin presented with chronic multi-
focal pneumonia and extensive moderate fibrosis, while none
of the untreated G2 and G4 Tert/ male mice and none of the
wild-type mice (both treated and untreated) examined showed
lung fibrosis (Figures 4D and 4E). As observed in the TRF1-defi-
cient model, we observed a gender bias toward more males
showing pulmonary fibrosis. In addition, macrophage infiltrates
and the induction of an inflammatory response, as determined
by F4/80 and interleukin-6 staining, respectively, were readily re-
vealed in G2Tert/ and G4Tert/ lungs treated with bleomycin
but absent in wild-type controls (Figure 4F). These findings were
further validated by determination of collagen fibers using sirius
red staining visualized by polarized light, which revealed3-fold
higher collagen deposits in the treated G2 and G4 Tert/ mice
as compared to untreated controls or wild-type mice (both
treated and untreated) (Figures 4G and 4H). Higher collagen
expression levels were also confirmed by RT-PCR in the telome-
rase-deficient lungs (Figure 4I). Furthermore, we detected
increased numbers of a-SMA-positive myofibroblasts in telome-
rase-deficient mice treated with bleomycin, which are indicative
of lung fibrosis (Zhang et al., 1996) (Figures 4J and 4K).
In agreement with the presence of pulmonary fibrosis in the
treated Tert/ mice, G2 and G4 Tert/ mice presented signifi-
cantly altered respiratory parameters when subjected to spirom-
etry compared with their corresponding untreated controls or
wild-type mice (Experimental Procedures). In particular, prior
to sacrifice, late-generation G2 Tert/ mice showed signifi-
cantly decreased tidal volume, inhaled minute volume, and expi-
ration influx compared to their corresponding untreated controls
and both treated and untreated wild-type mice (Figures 5A–5C).
To further investigate whether pulmonary fibrosis and lung
function impairment in G2 and G4 Tert/ mice were accompa-
nied by the presence of short telomeres, we performed telomere
qFISH directly on lung sections (Experimental Procedures). As
expected, G2 and G4 Tert/mice showed significantly lower in-
dividual telomere spot fluorescence and lower mean telomere
nuclear intensity as compared to wild-type controls. In addition,
a higher percentage of telomeres showing low fluorescence (<20
and <25 arbitrary units of fluorescence, corresponding to the
10th and 20th percentile of the G2 Tert/ telomere distribution)
was observed in G2 and G4 Tert/ cohorts as compared to
wild-type controls (Figures 5D–5H). Interestingly, treatment
with a low dose of bleomycin did not affect either mean telomere(F) Quantification of KFP-positive cells in Trf1+/+ and Trf1D/D lungs after 1, 2, and
(G) Quantification of p21-positive cells in Trf1+/+ and Trf1D/D lungs after 1, 2, and
(H) Quantification of p53, p19 and C3a positive cells in Trf1+/+ and Trf1D/D lungs
(I) Representative images of KFP (black arrowheads), p21 (purple arrowheads),
immunohistochemistry analysis of Trf1+/+ and Trf1D/D lungs 6–8 weeks after the
(J) Quantification of gH2AX-positive cells in Trf1+/+ after 1 week TMX treatment a
(K) Representative images of double immunofluorescence of gH2AX and TRF1 in
positive cells stain negative for TRF1 in Trf1D/D lung sections (white arrowheads)
p21-, p53-, and gH2AX-positive cells in (G), (H), and (J) are normalized to the num
represent SE. The number of mice analyzed per genotype is indicated. *p = 0.05fluorescence or the percent of telomeres with low fluorescence
in wild-type mice, indicating that this cellular damaging agent
does not include telomere shortening (Figures 5D–5H). Bleomy-
cin-treated G2 and G4 Tert/ mice showed a tendency toward
lower telomere fluorescence compared with untreated controls,
most likely as a consequence of additional cell divisions in the
absence of telomerase, but this trend did not reach statistical
significance (Figures 5D–5H). These results indicate that devel-
opment of pulmonary fibrosis in G2 and G4 Tert/mice treated
with a low dose of bleomycin requires of the presence of short
telomeres, as similarly treated wild-type mice do not develop
the disease. Nevertheless, the feature of having short telomeres
is not sufficient for disease onset and requires additional dam-
age. These results are in line with human findings showing that
damaging agents such as smoking increase the risk of devel-
oping pulmonary fibrosis associated with aging or telomerase
mutations (Armanios, 2013).
Bleomycin Enhances the DNA Damage Response in the
Lungs of Telomerase-Deficient Mice
To determine the amount of DNA damage induced by Tert defi-
ciency versus the combination of Tert deficiency and bleomycin,
we first studied presence of DNA damage foci (gH2AX) directly
on lung sections, as well as the presence of the senescence-
associated markers p21, p53, and p19 and the apoptotic marker
active caspase-3 (C3a). Of note, bleomycin treatment induced
DNA damage in all three genotypes (Figures 6A and 6F). Interest-
ingly, the burden of DNA damage wasmuch higher in the G2 and
G4 Tert/ mice treated with bleomycin (5% of total lung cells
in both cases) than in the untreated controls (less than 2% in both
cases) and was also higher than in the treated wild-type mice
(less than 1%) (Figures 6A and 6F). The increase in DNA damage
burden in bleomycin-treated G2-G4 Tert-deficient mice was
accompanied by increased percentage of cells with staining
positive for p53, p21, and p19, three well-established markers
of cell-cycle arrest and cellular senescence (Figures 6B–6D
and 6F). Similar to TRF1-depleted lungs, cell death by an
apoptotic mechanism was also revealed, as judged by the in-
crease in the number of C3a-positive cells in bleomycin-treated
Tert-deficient lungs (Figures 6E and 6F).
DISCUSSION
Our results show that severe telomere dysfunction, such as that
associated with TRF1 deficiency, which induces a high burden of
telomere-induced DNA damage (up to 10% of all lung cells
and >90% of alveolar type II cells), is sufficient for the6–8 weeks of tamoxifen (TMX) treatment.
6–8 of TMX treatment.
after 6–8 weeks of TMX treatment.
p53 (orange arrowheads), p19 (green arrowheads), and C3a (red arrowheads)
beginning of TMX treatment.
nd in Trf1D/D lungs after 1, 2, and 6–8 weeks of TMX treatment.
Trf1+/+ and Trf1D/D lungs after 6–8 weeks of TMX treatment. Notice that gH2AX-
.
ber of KFP-positive cells. A t test was used for statistical analysis. Error bars
; **p < 0.01; ***p < 0.001.
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Figure 4. A Low Bleomycin Dose Synergizes with Short Telomeres to Trigger Pulmonary Fibrosis
(A) Heterozygous Tert+/ mice were intercrossed to generate Tert+/+ and G1Tert/ mice. Successive crosses between G1Tert/ and G3Tert/ were set to
generate G2 Tert/ and G4Tert/ cohorts, respectively. 8- to 10-week-old Tert+/+, G2Tert/, and G4Tert/ mice were intratracheally inoculated either with
vehicle (PBS) (IT-Vh) or 0.5 mg/kg BW bleomycin (IT-Bl).
(B) In vivo follow-up of different mouse cohorts. At weeks 2, 6, and 10, mice were analyzed by computed tomography (CT), and at week 12, mice were sacrificed
for histological analysis.
(legend continued on next page)
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Figure 5. Decreased Pulmonary Capacity and Telomere Shortening in Lung Tissues of Telomerase-Deficient Mice
(A–C) Analysis of tidal volume (A), minute volume (B), and expiration flux at 50% (C) in Tert+/+ and G2Tert/ mice treated with either vehicle or 0.5 mg/kg BW
bleomycin.
(D–G) Individual mean telomere length (D), total mean nuclear telomere length (E), percentage of short telomeres <20 a.u.f. corresponding to the 10th percentile of
G2 Tert/ telomere distribution (E), and percentage of short telomeres <25 a.u.f. corresponding to the 20th percentile of G2 Tert/ telomere distribution (G) in
Tert+/+, G2Tert/, and G4Tert/ mice intratracheally inoculated either with vehicle (PBS) or 0.5 mg/kg BW bleomycin.
(H) Representative images of telomere qFISH analysis in Tert+/+, G2Tert/, and G4Tert/ bleomycin-treated lungs. Amplified images are shown in the insets.
A t test was used for statistical analysis. Error bars represent SE. The number of mice analyzed per genotype is indicated. *p = 0.05; **p < 0.01; ***p < 0.001.development of pulmonary fibrosis (Figure 7). In the case of short
telomeres owing to telomerase deficiency, however, additional
damage was required to develop full-blown pulmonary fibrosis
(Figure 7). In both models, we observed activation of the p53/(C) Determination of the maximum bleomycin dose that does not induce pulmon
2 weeks after intratracheal inoculation of bleomycin at a dose of 2.5 mg/kg BW,
(D) Representative H&E and Masson trichrome staining images of Tert+/+, G2T
bleomycin. To the right, amplified Masson trichrome images are shown.
(E) Percentage of mice of both genders or only males diagnosed with pulmonary
(F and G) Representative images of Tert+/+, G2Tert/, andG4Tert/ lung section
(F) and sirius red and visualized by bright-field and polarized light, where collage
(H) Percentage of lung area filled with collagen fibers.
(I and J) Quantification of a-SMA-positive myofibroblasts (I) and representative im
(K) Transcriptional levels of collagen expression in Tert+/+, G2Tert/, and G4Ter
A t test was used for statistical analysis. Error bars represent SE. The number ofp21 and p19ARF pathways, resulting in cell senescence and
apoptosis that lead to almost complete loss of alveolar type II
cells in the Trf1-deficient model. As both TERT and TRF1
deficiencies were previously shown to lead to decreasedary fibrosis in wild-type mice. Representative image of wild-type lung sections
1 mg/kg BW, 0.5 mg/kg BW, 0.1 mg/kg BW, or 0.0 mg/kg BW.
ert/, and G4Tert/ mice inoculated with either vehicle or 0.5 mg/kg BW
fibrosis by histopathological analysis.
s inoculatedwith 0.5mg/kg BWbleomycin stained with F4/80 and interleukin-6
n fibers are bright orange (G).
ages of wild-type, G2 Tert/, and G4 Tert/ lungs treated with bleomycin (J).
t/ bleomycin-treated lungs.
mice analyzed per genotype is indicated. *p = 0.05; **p < 0.01; ***p < 0.001.
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Figure 6. Bleomycin Enhances the DNA Damage Response in the Lungs of Telomerase-Deficient Mice
(A–E) Quantification of gH2AX- (A), p53- (B), p21- (C), p19- (D), and C3a-positive (E) cells in Tert+/+, G2Tert/, and G4Tert/ lungs inoculated either with vehicle
(PBS) or with 0.5 mg/kg BW bleomycin at time of death.
(F) Representative images of gH2AX, p53, p21, p19, and C3a immunohistochemistry staining in G4Tert/ lungs inoculated either with vehicle (PBS) or with
0.5 mg/kg BW bleomycin at time of death. A t test was used for statistical analysis.
Error bars represent SE. The number of mice analyzed per genotype is indicated. *p = 0.05; **p < 0.01; ***p < 0.001.ability of stem cells to regenerate tissues (Flores et al., 2005;
Schneider et al., 2013), increased cell loss associated to
severe telomere dysfunction is likely to trigger aberrant lung
healing by fibroblasts, eventually leading to scar formation and
pulmonary fibrosis. Based on our results, a DNA damaged
burden above a certain threshold (in both models was between
5% and 10% of total lung cells showing DNA damage), com-
bined with defective stem cell regeneration ability, may lead
to development of pulmonary fibrosis. Interestingly, we also
found that female mice were more resistant than male mice
to induction of pulmonary fibrosis associated with telomere
dysfunction in the TERT-deficient model, thus recapitulating
the human observations. Our results clearly demonstrate
that induction of telomere dysfunction upon Trf1 deletion in
type II alveolar cells is sufficient to induce pulmonary fibrosis.
In the case of the telomerase-deficient mouse model, it is likely
that application of low-dose bleomycin induces DNA damage296 Cell Reports 12, 286–299, July 14, 2015 ª2015 The Authorsgenome-wide, and telomere dysfunction might not constitute
the only driving pathogenic mechanism underlying pulmonary
fibrosis.
Our results and those of others show that treatment with a
high bleomycin dose (>1 mg/kg) induces DNA damage
above the tolerated threshold in wild-type mice, leading to pul-
monary fibrosis in both wild-type and TERT-knockout mice
(Degryse et al., 2012). However, a low bleomycin dose, such
as the one used here, is well tolerated by wild-type mice
but causes pulmonary fibrosis in telomerase-knockout mice
that present a basal DNA damage due to short telomeres.
In a previous study, it was reported that telomerase activity
was required for bleomycin-induced pulmonary fibrosis in
mice (Liu et al., 2007). These results stand in contrast with
both our work and that of Degryse et al. (Degryse et al.,
2012), since telomerase deficiency never led to protection
from fibrosis development. In a recent study, it was shown
Figure 7. Model for Pulmonary Fibrosis
Associated with Telomeric DNA Damage
Depletion of TRF1 protein (red circle) from telo-
meres (orange rectangle) in lung alveolar type II
cells leads to a persistent and severe DNA damage
response at telomeres characterized by increased
gH2AX (purple star) in 10% of total lung cells and
up to 90% of alveolar type II cells and activation of
the p53/p21 pathway. Application of a low dose of
bleomycin (0.5 mg/kg BW) to wild-type lungs does
not lead to a significant increase in the number of
damaged cells (less than 1% of total lung cells).
The same bleomycin dose in telomerase-deficient
mice with short telomeres significantly enhances
the DNA damage burden in lung cells, with 6% of
total lung cells showing DNA damage, and leads
to activation of the p53/p21 pathway. In both
models, cell loss mediated by senescence and
apoptosis and impaired regeneration may lead to
aberrant lung healing and formation of fibrotic
stars.that telomere dysfunction impairs lung stem function by
inducing senescence, ultimately leading to an inflammatory
response and susceptibility to lung injury, although in this
model, the authors did not observe the development of pulmo-
nary fibrosis, most likely because they challenged mice with a
high dose of bleomycin (>1 mg/kg BW) (Alder et al., 2015). In
this scenario, over 60% of the mice, including wild-type con-
trols, died during the first 2 weeks due to acute epithelial injury,
indicating that the DNA damage burden was too high and
incompatible with life. The authors did not address the effect
of Trf2 deletion in adulthood without any additional challenge
with bleomycin (Alder et al., 2015).
Together, these findings support a model for the pathobi-
ology of human disease by which persistent DNA damage
steaming from short or dysfunctional telomeres associated
with either telomere syndromes or organismal aging can syner-
gize with additional cellular damage in order to trigger
pulmonary fibrosis (Figure 6). We also show that a high burden
of telomeric DNA damage induced by severe telomere dysfunc-
tion, in the absence of telomere shortening, is sufficient to
trigger pulmonary fibrosis in the absence of any additionalCell Reports 12, 286–DNA damage in the genome. Finally,
the mouse models generated here are
instrumental for the preclinical testing of
therapeutic strategies based in telome-
rase activation or correction of telomere
uncapping.
EXPERIMENTAL PROCEDURES
Mice and Animal Procedures
Trf1flox/floxmicewere generated as described previ-
ously (Martı´nez et al., 2009). To conditionally delete
Trf1 from alveolar epithelial type II (AEC II) cells, ho-
mozygousTrf1flox/floxmicewere crossedwith trans-
genic mice expressing Cre-ERT2 under the control
of theSFTPCpromoter (Rocket al., 2011) aswell as
with transgenicmice harboring the fluorescent KFPprotein-encoding gene that contains a stop cassette flanked by lox sequences,
the KFPCAG-lox-STOP-lox allele (Die´guez-Hurtado et al., 2011). Heterozygous
Trf1flox/+ SFTPC-CreERT2 KFPCAG-lox-STOP-lox mice were crossed with Trf1+/flox
mice to obtain Trf1+/+ SFTPC-Cre-ERT2 KFPCAG-lox-STOP-lox and Trf1flox/flox
SFTPC-CreERT2 KFPCAG-lox-STOP-lox mice.
Tert-Knockout and Wild-Type Mice
Wild-type mice and Tert/ mice of pure C57/BL6 background were used
for the bleomycin intratracheal inoculation procedure. Tert-heterozygous
mice generated as previously described (Liu et al., 2000) were backcrossed
to >98% C57/BL6 background. Tert+/ mice were intercrossed to generate
G1 homozygous Tert/-knockout mice. G2 and G4 Tert/ mice were
generated by successive breeding of G1Tert/ and G3Tert/ mice,
respectively.
All mice were produced and housed at the specific-pathogen-free barrier
area of the CNIO, Madrid. All animal procedures were approved by the
CNIO-ISCIII Ethics Committee for Research and Animal Welfare (CEIyBA)
and conducted in accordance to the recommendations of the Federation of
European Laboratory Animal Science Associations (FELASA).
TMX Treatment
TMXwas dissolved in corn oil to a concentration of 20 mg/ml. 8- to 10-week-old
Trf1flox/flox SFTPC-Cre-ERT2 KFPT/+ and Trf1+/+ SFTPC-Cre-ERT2 KFPT/+ mice
were i.p. inoculated with 50 ml (1 mg per injection) TMX solution three times
per week for 6 weeks.299, July 14, 2015 ª2015 The Authors 297
Bleomycin Titration and Inoculation
Decreasing bleomycin concentrations (2.5 mg/kg BW, 1mg/kg BW, 0.5 mg/kg
BW, and 0.1 mg/kg BW) were intratracheally inoculated into 8- to 10-week-old
wild-type mice. 2 weeks after the inoculation, mice were sacrificed and
analyzed by immunohistochemistry for pulmonary fibrosis.
A low dose of bleomycin (0.5 mg/kg BW) or PBS was inoculated into 8- to
10-week-old wild-type, G2 Tert/, and G4 Tert/ mice.
Histopathology, Immunohistochemistry, and Immunofluorescence
Analysis
Histopathological analysis of paraffin-embedded lungs was performed in lung
sections stained with H&E and Masson trichrome using standard procedures.
To quantify collagen deposition, sirius red staining was performed on deparaf-
finized slides with picrosirius red solution for 1 hr (Broytman et al., 2015).
Immunohistochemistry stainings were performed with the following primary
antibodies: rat monoclonal to p53 (POE316A/E9; CNIO histopathology core
unit), rat monoclonal to p21 (HUGO-291H/B5; CNIO histopathology core
unit), mouse monoclonal to phospho-histone H2AX (Ser139) (Millipore), rat
monoclonal to F4/80 (ABD Serotec), p19ARF (5-C3-1 Santa Cruz Biotech-
nology), activated caspase-3 (R&D Systems), interleukin-6 (ab6672, Abcam),
and rabbit polyclonal turbo-RFP (Evrogen).
For immunofluorescence, the antibodies used were a rabbit polyclonal anti-
TRF1 (homemade), phospho-H2AX Ser 139 (05-636, Millipore), goat poly-
clonal anti SPC (C-19, Santa Cruz Biotechnology), a-SMA (CME 305, Biocare
Medical), and mouse monoclonal anti KFP (RF5R, Abcam). Images were ob-
tained using a confocal ultraspectral microscope (Leica TCS-SP5). Fluores-
cence intensities were analyzed with Definiens software.
Lung In Vivo Imaging by CT
The acquisition was made on a high-resolution CT system (CT Locus, GE
Healthcare) specially designed for small laboratory animals. Mice were anes-
thetized with a 4% rate of isoflurane (IsoVet Braun) during the induction and
2% during the maintenance period (scanning time). Micro-CT image acquisi-
tion consisted of 400 projections collected in one full rotation of the gantry dur-
ing 14 min in a single bed focused on the legs, with a 450-mA/80-kV X-ray
tube. 2D and 3D images were obtained and analyzed using the software pro-
gramMicroView (GE Healthcare). All procedures were carried out according to
the European Normative of Welfare and Good Practice (2010/63/UE).
Spirometry Analysis
Wild-type and G2 Tert/ mice were placed into a head-out single chamber
plethysmograph (Harvard Apparatus) for 3–5 min. Data acquisition was per-
formed by Pulmodyn W software (from Hugo Sachs Elektronic Harvard
Apparatus).
Transcriptional Analysis in Paraffin-Embedded Lungs
RNA was extracted from two lung paraffin block sections of 20 mm with a
RNeasy FFPE kit following the manufacturer’s instructions (QIAGEN, catalog
number 73504). cDNA was synthesized, and collagen I and III expression was
analyzed by qPCR. The primers used for Col1a1 were Col1a-F (50-GCCACTCT
GACTGGAAGAGC-30) andCol1a-R (50-CAGCCTTGGTTAGGGTCGAT-30). The
primers used for Col3a1 were Col3a1-F (50AAATTCTGCCACCCCGAACT-30 )
and Col3a-R (50-AGCCTTGGTTAGGATCAACCC-30).
Telomere Analysis
qFISH determination on paraffin-embedded tissue sections was performed as
described previously (Gonza´lez-Sua´rez et al., 2000). After deparaffinization,
tissues were post-fixed in 4% formaldehyde for 5 min, washed three times
(5 min each) in PBS, and incubated at 37C 15 min in pepsin solution (0.1%
porcine pepsin, Sigma; 0.01 M HCl, Merck). After another round of washes
and fixation as previously mentioned, slides were dehydrated in a 70%-
90%-100% ethanol series (5 min each). After 10 min of air-drying, 30 ml telo-
mere probe mix (10 mM TrisCl [pH 7], 25 mM MgCl2, 9 mM citric acid,
82 mMNa2HPO4, 70% deionized formamide [Sigma], 0.25% blocking reagent
[Roche], and 0.5 mg/ml telomeric PNA probe [Panagene]) was added to each
slide. A coverslip was added, and slides were incubated for 3 min at 85C
and for an additional 2 hr at room temperature in a wet chamber in the dark.298 Cell Reports 12, 286–299, July 14, 2015 ª2015 The AuthorsSlides were washed two times (15 min each) in 10 mM TrisCl (pH 7), and
0.1% BSA in 70% formamide under vigorous shaking and three times (5 min
each) in TBS 0.08% Tween20 and then incubated in a DAPI bath (4 mg/ml
DAPI [Sigma] in PBS) before mounting samples in Vectashield (Vector).
Confocal images were acquired as stacks every 1 mm for a total of 3 mm using
a Leica SP5-MP confocal microscope, and maximum projections were done
with the LAS-AF software. Telomere signal intensity was quantified using
Definiens software.
Statistical Analysis
An unpaired Student’s t test was used to calculate statistical significance of
p21, p53, p19, C3a, and gH2AX markers by immunohistochemistry and inter-
stitial fibrosis by sirius red staining. A log-rank test was used to calculate the
statistical differences in the survival curves of the different mice cohorts.
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